Nivolumab-associated bone marrow necrosis

Ann Oncol. 2018 Feb 1;29(2):513-514. doi: 10.1093/annonc/mdx643.

Authors

T Hilal¹, P Bansal², K Kelemen³, J Slack⁴

Affiliations

¹ Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, USA. Electronic address: hilal.talal@mayo.edu.
² Division of Hematology/Oncology, University of New Mexico, Albuquerque, USA.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, USA.
⁴ Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, USA.

PMID: 29351576
DOI: 10.1093/annonc/mdx643

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Bone Marrow / pathology*
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Male
Middle Aged
Necrosis
Nivolumab / adverse effects*

Substances

Antineoplastic Agents, Immunological
Nivolumab